title: Molecular heterogeneity of pro-atrial natriuretic factor.
abstract: Analysis by two-dimensional gel electrophoresis and Western blotting of the atrial natriuretic factor (ANF) content of atrial granules revealed the presence of at least 15 immunoreactive spots whose molecular mass distribution ranged from 16.8 to 35 kDa and their pI values from 5.12 to 5.98. About 90% of the immunoreactive ANF material was contained within four spots (spot 1: 34.8 kDa, pI 5.67; spot 5: 16.8 kDa, pI 5.50; spot 6: 16.8 kDa, pI 5.67; spot 7: 16.8 kDa, pI 5.98). Investigation of the molecular nature of spot 1 indicated that it is a dimer of pro-ANF since it possesses the same immunoreactivity, the same charge, double its mass, and can be converted with dithiothreitol into a 16.8-kDa pro-ANF form. Alkaline phosphatase and protein kinase A treatments indicated that spots 5, 6, and 7 are probably not phosphorylated forms of pro-ANF. Carboxypeptide A and B treatments in conjunction with amino acid analysis suggested that spot 7 is ANF-(1-128); spot 6, the major one, ANF-(1-126); and spot 5, ANF-(1-123) or ANF-(1-124). Water deprivation or morphine injection, two maneuvers which are known to influence ANF secretion and atrial ANF content, failed to affect the molecular heterogeneity of pro-ANF except for spot 1. The formation of the dimer appeared to be time-dependent. These results emphasize the heterogeneity of the pro-ANF molecule stored in atrial granules. We suggest that this heterogeneity may be due, in part, to the action of some proteases, such as carboxypeptidase E or a tripeptidyl carboxyhydrolase.
authors.affiliation: Clinical Research Institute of Montréal, Québec, Canada.
authors.forename: G
authors.initials: G
authors.lastname: Thibault
authors.forename: C
authors.initials: C
authors.lastname: Lazure
authors.forename: M
authors.initials: M
authors.lastname: Chrétien
authors.forename: M
authors.initials: M
authors.lastname: Cantin
mesh_terms: D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000302:isolation & purification* / Q000378:metabolism; D015153:Blotting, Western; D043424:Carboxypeptidase B; D002268:Carboxypeptidases / Q000378:metabolism; D043422:Carboxypeptidases A; D004229:Dithiothreitol / Q000494:pharmacology; D015180:Electrophoresis, Gel, Two-Dimensional; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D006325:Heart Atria / Q000032:analysis; D007526:Isoelectric Point; D008970:Molecular Weight; D009206:Myocardium / Q000032:analysis*; D010446:Peptide Fragments / Q000302:isolation & purification / Q000378:metabolism; D011494:Protein Kinases / Q000378:metabolism; D011498:Protein Precursors / Q000302:isolation & purification* / Q000378:metabolism; D011817:Rabbits
chemical_list: D010446:Peptide Fragments; D011498:Protein Precursors; D009320:Atrial Natriuretic Factor; D011494:Protein Kinases; D000469:Alkaline Phosphatase; D002268:Carboxypeptidases; D043422:Carboxypeptidases A; D043424:Carboxypeptidase B; D004229:Dithiothreitol